Melanoma and other skin tumours


Relatlimab (RELA) + Nivolumab (NIVO) Vs. NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Efficacy in RELATIVITY-047

F.S. Hodi, et al.


RELA + NIVO FDC had demonstrated prolonged PFS in ITT and subgroups of pts with previously untreated metastatic or unresectable melanoma. Pts on RELA + NIVO FDC had enduring benefit beyond initial treatment and prolonged benefit beyond first progression, including longer time to initiation of subsequent treatment.



Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

J.S. Weber, et al.


Flipped dose IPI/NIVO with TOCI has promising anti-tumor activity with a favorable toxicity profile. Incidence of grade 3/4 irAEs was 25%. High baseline TNF-a was associated with grade 3/4 irAEs, and elevated week 7 IL-6/IL-8/C5a were associated with progression. Further correlative studies will be presented.



MASTERKEY-265: A phase 3, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)



T + P did not significantly improve PFS or OS vs Pbo + P. There was a 5.8 mo numeric difference in PFS between arms. Safety results of T + P were acceptable and consistent with the known safety profiles of each agent.